会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 17. 发明申请
    • INHIBITION OF PCSK9 THROUGH RNAI
    • 通过RNAi抑制PCSK9
    • US20130197055A1
    • 2013-08-01
    • US13143275
    • 2010-01-05
    • Joanne KamensAnastasia Khvorova
    • Joanne KamensAnastasia Khvorova
    • C12N15/113
    • C12N15/1137C12N2310/14C12N2310/315C12N2310/321C12N2310/322C12N2310/344C12N2310/3515C12N2310/531C12N2320/11C12Y304/21061C12Y304/21112C12N2310/3521C12N2310/3533
    • The invention relates to various PCSK9 RNAi constructs with gene silencing activities, and uses thereof The construct has a double-stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity The sense strand may be modified such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC In addition, the antisense strand may also be modified by 2′-O-methyl groups at the 2nd 5′-end nucleotide to greatly reduce off-target silencing The constructs of the invention largely avoid the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity.
    • 本发明涉及具有基因沉默活性的各种PCSK9 RNAi构建体及其用途。该构建体具有19-49个核苷酸,优选25,26或27个核苷酸的双链区域,优选为平端。该构建体具有选择性最小修饰 赋予生物活性,毒性,稳定性和靶基因特异性的最佳平衡有义链可以被修饰,使得构建体不被切丝虫或其他RNA酶III切割,并且反义链的整个长度被加载到RISC In 此外,反义链也可以在第二个5'-末端核苷酸处被2'-O-甲基修饰,以大大减少脱靶沉默本发明的构建体大大地避免了哺乳动物细胞中的干扰素应答和序列无关的凋亡 ,表现出更好的血清稳定性和增强的靶特异性。